Nathan Sweeney is a senior scientist at GSK working in the cell and gene therapy department. He leads a project aimed at building and maintaining a world class lentivirus vector manufacturing platform based on GSKs stable cell line technology. His primary area of expertise is molecular virology of retroviruses.
Prior to joining GSK three years ago, Nathan completed a post-doctoral position and PhD at Imperial College London, working on gene therapy approaches for lysosomal storage diseases and muscular dystrophy. His first degree was at the University of Warwick where he studied Biological Sciences with specialisation in virology.